Key facts
- This page summarizes Alan Colman's Form 4 filing for VOLITIONRX LTD (VNRX).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 31 Jan 2025, 16:06.
Alan Colman - 29 Jan 2025 Form 4 Insider Report for VOLITIONRX LTD (VNRX)
- Reporting relationship
- Director
- Issuer ticker
- VNRX
- Reported as of
- 29 Jan 2025
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 31 Jan 2025, 16:06:09 UTC
- Prior SEC filing
- 03 Dec 2024
- Next SEC filing
- 04 Mar 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Alan Colman
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Alan Colman filed Form 4 for VOLITIONRX LTD (VNRX) on 31 Jan 2025.
Change
- Previous filing in this sequence was filed on 03 Dec 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
VNRX
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- Shares
- -25,000
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 29 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,000
- Exercise price
- $3.25
- Footnotes
- F1
VNRX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- Shares
- +25,000
- Change %
- Price
- Shares after
- 25,000
- Date
- 29 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 25,000
- Exercise price
- $3.25
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The reported transaction involved an amendment of outstanding options, resulting in the deemed cancellation of the "old" options and the grant of "replacement" options. The "old" options were originally granted on February 11, 2019, vested in full and were exercisable at 12 months from the date of grant, and were exercisable for five years from the date first exercisable. The "replacement" options are fully-vested and expire on February 11, 2029 (ten years from the original date of grant).